Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

ClearBridge Investments 2.27K Followers Follow Summary Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs. Biotech funding and CRO demand are recovering, with CRL and ICLR poised to benefit from improving preclinical and clinical trial activity. Bioprocessing growth and potential U.S. reshoring favor TMO, DHR, and SSSGY, while utilization normalization creates selective opportunities across devices and managed care. jittawit.21/iStock via Getty Images By Marshall Gordon, Brittany Henderson, and Nick Wu, PhD After several challenging years, important parts of the health care sector appear to be reaching an inflection point. Policy uncertainty has weighed on pharmaceutical companies, constrained biotech funding has This article was written by ClearBridge Investments 2.27K Followers Follow ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We convey these ideas to investors on a frequent basis through investment commentaries and thought leadership and look forward to sharing the latest insights from our white papers, blog posts as well as videos and podcasts. Analyst’s Disclosure: I/we have a beneficial long position in the shares of CRL, SSSGY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Past performance is no guarantee of future results. All opinions and data included in this document are as of the publication date and are subject to change. The opinions and views expressed herein are of the author(s) and may differ from other managers or the firm as a whole and are not intended to be a forecast of future events, a guarantee of future results, or investment advice. This information should not be used as the sole basis to make any investment decision. The statistics have been obtained from sources believed to be reliable, but the accuracy and completeness of this information cannot be guaranteed. Neither ClearBridge Investments, LLC nor its information providers are responsible for any damages or losses arising from any use of this information. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.